Related Experiment Video

Updated: May 6, 2026

Creation of a Knee Joint-on-a-Chip for Modeling Joint Diseases and Testing Drugs
12:44

Creation of a Knee Joint-on-a-Chip for Modeling Joint Diseases and Testing Drugs

Published on: January 27, 2023

3.6K

The future of osteoarthritis therapeutics: emerging biological therapy

A Mobasheri1

  • 1D-BOARD European Consortium for Biomarker Discovery, Faculty of Medicine and Health Sciences, The University of Nottingham, Nottingham, UK, ali.mobasheri@nottingham.ac.uk.

Current Rheumatology Reports
|October 31, 2013
PubMed

Insights

Emerging biological therapies show promise for osteoarthritis (OA), shifting focus from "wear and tear" to inflammation. Research targets include inflammation, angiogenesis, and neurogenesis in OA.

Area of Science:

  • Rheumatology and immunology
  • Orthopedics
  • Regenerative medicine

Background:

  • Osteoarthritis (OA) is increasingly recognized as an inflammatory condition, moving beyond the traditional

Purpose of the Study:

  • To review emerging biological therapies for osteoarthritis (OA).
  • To discuss novel molecular targets and therapeutic strategies for OA.
  • To highlight progress in antibody-based therapy, calcitonin, and kartogenin for OA.

Main Methods:

  • Literature review of recent research on biological therapy for OA.
  • Analysis of molecular targets in angiogenesis and neurogenesis relevant to OA.
  • Evaluation of current therapeutic approaches including antibody-based therapy, calcitonin, and kartogenin.

Main Results:

  • OA pathogenesis involves low-grade inflammation, angiogenesis, and neurogenesis.
  • Several biological targets are being investigated for OA treatment.
  • Promising therapeutic agents include antibody-based therapies, calcitonin, and kartogenin.

Conclusions:

  • Biological therapies offer a new avenue for treating osteoarthritis, targeting underlying inflammatory and degenerative processes.
  • Further research into molecular targets like angiogenic and neurogenic factors is crucial for developing effective OA treatments.
  • Emerging therapies like kartogenin show potential for stimulating cartilage regeneration in OA.

More Related Videos

Characterization of Intra-Cartilage Transport Properties of Cationic Peptide Carriers09:02

Characterization of Intra-Cartilage Transport Properties of Cationic Peptide Carriers

Published on: August 10, 2020

6.8K

Related Concept Videos

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF01:24

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
897
Microorganisms in Medicine and Therapeutics01:29

Microorganisms in Medicine and Therapeutics

Microorganisms play a fundamental role in vaccine development, gene therapy, and therapeutic production. Their biological properties are harnessed to advance medicine and public health. Beyond immunization, microorganisms contribute to gut health, antibiotic synthesis, and genetic disease treatment.Live Attenuated and Inactivated VaccinesLive attenuated vaccines, such as the measles, mumps, and rubella (MMR) vaccine, utilize weakened forms of pathogens to closely resemble natural infections.
1.4K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.1K
Degenerative Disc Disease ll: Pathophysiology01:23

Degenerative Disc Disease ll: Pathophysiology

The symptoms of degenerative disc disease arise from a combination of mechanical compression, vascular compromise, and biochemical inflammation, which together disrupt nerve function and produce pain.Mechanical CompressionDisc degeneration reduces height and elasticity, predisposing to herniation of the nucleus pulposus, a major cause of radicular pain. Herniations may be protrusion (bulging with intact annulus), extrusion (nucleus extends beyond disc but remains connected), or sequestration...
36
Inflammatory Bowel Disease IV: Pharmacological Management01:29

Inflammatory Bowel Disease IV: Pharmacological Management

Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
1.1K
Mesenchymal Stem Cells01:19

Mesenchymal Stem Cells

Mesenchymal stem cells (MSCs) are adult stem cells that can differentiate into most connective tissue cell types, except for hematopoietic cells, depending upon the source of MSCs. For example, bone-marrow-derived MSCs (BM-MSCs) can differentiate into osteocytes, hepatocytes, and pancreatic and neuronal cells. MSCs can be isolated from various sources such as bone marrow, placenta, adipose tissue, teeth, and Wharton’s jelly, a gelatinous substance in the umbilical cord. The ease of their...
4.5K